Literature DB >> 25382211

The relationship between circulating irisin levels and endothelial function in lean and obese subjects.

Ningning Hou1, Fang Han2, Xiaodong Sun1.   

Abstract

OBJECTIVE: Irisin has been shown to turn white adipocytes into brown-like adipocytes, which is emerging as an appealing therapeutic target for obesity. The objective of the study was to determine whether circulating irisin levels are related to endothelial dysfunction in obese subjects.
DESIGN: A total of 41 nonhypertensive, nondiabetic obese subjects and 40 age- and sex-matched lean healthy control were involved in this study. Clinical characteristics, blood biochemistry, circulating irisin and adiponectin of the subjects were measured. Endothelium-dependent vasodilation (EDV) and endothelial-independent vasodilation (EIV) were determined using high-resolution ultrasound.
RESULTS: Circulating irisin and adiponectin were significantly lower in obese subjects compared with lean healthy control (P < 0·05). Endothelial function was impaired in obese subjects (maximum EDV: 8·95 ± 3·46% vs 14·56 ± 3·90%, P < 0·05). Bivariate correlation analysis revealed that circulating irisin was positively correlated with EDV(r = 0·388, P < 0·01) and negatively correlated with BMI (r = -0·281, P < 0·05), waist circumference (r = -0·298, P < 0·01), free fatty acid (FFA) (r = -0·289, P < 0·01), high-sensitivity C-reactive protein (hs-CRP) (r = -0·244, P < 0·05) and malondialdehyde (r = -0·258, P < 0·05). Multiple regression analysis revealed that circulating irisin, adiponectin, FFA and BMI were independently associated with EDV after adjusting for covariates (R(2) = 0·457, F = 8·766, P = 0·000).
CONCLUSIONS: Circulating irisin level was decreased in nonhypertensive, nondiabetic obese subjects compared with lean healthy control. Lower levels of irisin are independently associated with endothelial dysfunction. Therefore, irisin may be involved in the regulation of endothelial function in obesity.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25382211     DOI: 10.1111/cen.12658

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  19 in total

Review 1.  Irisin in metabolic diseases.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis; Zoe A Efstathiadou; Polyzois Makras; Nikolaos Perakakis; Jannis Kountouras; Christos S Mantzoros
Journal:  Endocrine       Date:  2017-11-23       Impact factor: 3.633

Review 2.  Does iris(in) bring bad news or good news?

Authors:  Silvio Buscemi; Davide Corleo; Carola Buscemi; Carla Giordano
Journal:  Eat Weight Disord       Date:  2017-09-20       Impact factor: 4.652

3.  Association of serum irisin concentrations with the presence and severity of obstructive sleep apnea syndrome.

Authors:  Yanli Li; Xueqin Li; Dejun Sun; Shaoxi Cai
Journal:  J Clin Lab Anal       Date:  2016-10-11       Impact factor: 2.352

4.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

5.  Decreased Concentration of Irisin Is Associated with Poor Functional Outcome in Ischemic Stroke.

Authors:  Wen-Jun Tu; Han-Cheng Qiu; Jian-Lei Cao; Qiang Liu; Xian-Wei Zeng; Ji-Zong Zhao
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

6.  Exercise training with dietary restriction enhances circulating irisin level associated with increasing endothelial progenitor cell number in obese adults: an intervention study.

Authors:  Junhao Huang; Shen Wang; Fengpeng Xu; Dan Wang; Honggang Yin; Qinhao Lai; Jingwen Liao; Xiaohui Hou; Min Hu
Journal:  PeerJ       Date:  2017-08-14       Impact factor: 2.984

7.  The impact of long-term changes in metabolic status on cardiovascular biomarkers and microvascular endothelial function in middle-aged men: a 25-year prospective study.

Authors:  Magdalena Kwaśniewska; Joanna Kozińska; Elżbieta Dziankowska-Zaborszczyk; Tomasz Kostka; Anna Jegier; Ewa Rębowska; Milena Orczykowska; Joanna Leszczyńska; Wojciech Drygas
Journal:  Diabetol Metab Syndr       Date:  2015-09-17       Impact factor: 3.320

8.  Irisin Inhibits Hepatic Cholesterol Synthesis via AMPK-SREBP2 Signaling.

Authors:  Hong Tang; Ruili Yu; Shiying Liu; Bahetiyaer Huwatibieke; Ziru Li; Weizhen Zhang
Journal:  EBioMedicine       Date:  2016-02-27       Impact factor: 8.143

9.  Irisin Inhibits Atherosclerosis by Promoting Endothelial Proliferation Through microRNA126-5p.

Authors:  Yuzhu Zhang; Haibo Song; Yuan Zhang; Fei Wu; Qian Mu; Miao Jiang; Fang Wang; Wen Zhang; Liang Li; Lei Shao; Shiwu Li; Lijun Yang; Mingxiang Zhang; Qi Wu; Dongqi Tang
Journal:  J Am Heart Assoc       Date:  2016-09-26       Impact factor: 5.501

Review 10.  Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction.

Authors:  Raffaele Altara; Mauro Giordano; Einar S Nordén; Alessandro Cataliotti; Mazen Kurdi; Saeed N Bajestani; George W Booz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-07-17       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.